LAS VEGAS,
March 3, 2014 /CNW/ - Vansen
Pharma Inc. [OTCQB: VNSN], a specialty pharmaceutical company,
is pleased to announce the appointment of Dr. Ahmad Doroudian as its President and Chief
Executive Officer. Dr. Doroudian was most recently the Chief
Executive Officer and Vice Chairman of Merus Labs International
Inc. (NASDAQ:MSLI - TSX:MSL), and brings with him a track record of
accomplishment and success earned over his career in the healthcare
industry.
Prior to founding Merus Labs, Dr. Doroudian
served in various leadership positions at several pharmaceutical
companies. Most notably he was the founder, CEO, Chairman and
Director of PanGeo Pharma Inc. (now PendoPharm, a division of
Pharmascience Inc.) Dr. Doroudian has been involved with early
stage financing and management of private and publicly listed
companies since 1996 and holds a Bachelors Degree in Biochemistry
and a Masters Degree and Ph.D. in Biopharmaceutics from the
University of British Columbia.
Dr. Doroudian will join Dr. Patrick Frankham on Vansen's Board of Directors.
Dr. Frankham currently serves as "Executive Director, Business
Model & Healthcare Innovation" at Boehringer Ingelheim, one of
the world's 20 leading pharmaceutical companies. Dr. Frankham has
developed and marketed products in several therapeutic areas
including anti-infectives, ophthalmology, dermatology, oncology,
endocrinology and CNS. Notable prior organizations where he
held leadership roles include Phoenix International Life Sciences
(MDS Pharma Services), Endoceutics Inc., Aeterna Zentaris, BioAxone
Biosciences, & ICON Clinical Research.
Moira Ong also
joins Vansen's management team as Chief Financial Officer. Ms. Ong
is a Chartered Accountant with over 16 years of experience in
accounting and consulting and was formerly Vice President of
Finance at Merus Labs International Inc. In addition to holding her
Chartered Accountant (CPA, CA) designation, Ms. Ong is also a
Chartered Financial Analyst (CFA).
About Vansen Pharma Inc.
Vansen Pharma Inc. is a specialty pharmaceutical
company focused on broad therapeutic areas that are anticipated to
grow and present an opportunity for major expansion. Vansen
will expand its commercial presence by adding complimentary
products through in-licensing, co-promotion and acquisitions,
resulting in a comprehensive product portfolio. With its US
based sales force, Vansen can better serve the increasing
healthcare needs of patients and enhance growth. Vansen's
current product portfolio of anti-infectives, including Factive®,
Spectracef® and Cefditoren Pivoxil®, provides a strong and stable
revenue base from which to grow and expand our company. Our
experienced management team is aggressively pursuing acquisitions
of accretive specialty products, including legacy drugs and cash
flow positive healthcare companies. We look forward to
executing our growth strategy and creating lasting shareholder
value for our investors.
Cautionary Statement
Certain statements contained in this press
release may constitute "forward-looking statements" within the
meaning of Section 21E (i) (1) of the United States Securities
Exchange Act of 1934. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause
Vansen's actual results to be materially different from any future
results expressed or implied by these statements. Such statements
include but are not limited to, that Vansen will expand its
commercial presence by adding complimentary products through
in-licensing, co-promotion and acquisitions, resulting in a
comprehensive product portfolio, or that Vansen's current product
portfolio will provide a strong and stable revenue base from which
to grow and expand the company. Such factors include the following:
general economic and business conditions, changes in demand for
Vansen's products, changes in competition, the ability of Vansen to
integrate acquisitions or complete future acquisitions, interest
rate fluctuations, currency exchange rate fluctuations, dependence
upon and availability of qualified personnel and changes in
government regulation. In light of these and other uncertainties,
the forward-looking statements included in this press release
should not be regarded as a representation by Vansen that Vansen's
plans and objectives will be achieved. These forward-looking
statements speak only as of the date of this press release, and we
undertake no obligation to update or revise the statements.
SOURCE Vansen Pharma Inc.